Stockscreener 앱 받기
1.315
2.99%
-0.025
전일 마감가:
$1.34
열려 있는:
$1.37
하루 거래량:
873.88K
Relative Volume:
0.55
시가총액:
$121.34M
수익:
$34.48M
순이익/손실:
$-102.07M
주가수익비율:
-0.9007
EPS:
-1.46
순현금흐름:
$-104.90M
1주 성능:
-14.47%
1개월 성능:
-19.25%
6개월 성능:
-43.48%
1년 성능:
-78.58%
1일 변동 폭
$1.30
$1.37
1주일 범위
$1.30
$1.55
52주 변동 폭
$1.30
$8.33
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
CRBU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.30 | 121.34M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.19 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.84 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.41 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Caribou Biosciences stock hits 52-week low at $1.32 - Investing.com
2025-01-29 | Levi & Korsinsky Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:CRBU | Press Release - Stockhouse Publishing
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewswire
2025-01-29 | Investors who Lost Money on Caribou Biosciences, Inc. (CRBU) Should Contact Levi & Korsinsky About Pending Class ActionCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
2025-01-28 | Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesCRBU - PR Newswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit - PR Newswire
Shareholders that lost money on Caribou Biosciences, Inc. - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
FY2025 Earnings Estimate for CRBU Issued By Leerink Partnrs - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Sold by JPMorgan Chase & Co. - Defense World
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, - GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Leerink Partnrs Has Negative Outlook of CRBU FY2025 Earnings - MarketBeat
Caribou Biosciences, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - Victoria Advocate
Equities Analysts Offer Predictions for CRBU FY2025 Earnings - Defense World
Caribou Biosciences stock hits 52-week low at $1.49 - MSN
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc.(CRBU) Shareholders - PR Newswire
Caribou Biosciences stock hits 52-week low at $1.49 By Investing.com - Investing.com Canada
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to - The Bakersfield Californian
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewswire
Contact Levi & Korsinsky by February 24, 2025 Deadline to Join Class Action Against Caribou Biosciences, Inc. (CRBU) - GlobeNewswire
Investors who lost money on Caribou Biosciences, Inc.(CRBU) - GlobeNewswire
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for InvestorsContact Levi & Korsinsky - GuruFocus.com
Barclays PLC Has $255,000 Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCRBU - Markets Insider
2025-01-20 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. LawsuitCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineCRBU - Stockhouse Publishing
Faruqi & Faruqi Reminds Caribou Biosciences Investors of - GlobeNewswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) - GlobeNewswire
CRBU LAWSUIT ALERT: The Gross Law Firm Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Finansavisen
CRBU INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In CRBU To Contact Him Directly To Discuss Their Options - PR Newswire
CRBU Stockholders Have Opportunity to Lead Caribou Biosciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - Morningstar
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Markets Insider
Caribou Biosciences, Inc. Shareholders are Encouraged to - GlobeNewswire
Caribou Biosciences, Inc. Securities Fraud Class Action - GlobeNewswire
Caribou Biosciences Advances CAR-T Therapy Trials - TipRanks
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your RightsCRBU - PR Newswire
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
Caribou Biosciences Launches GALLOP Trial for Lupus, Reports Strong Pipeline Progress & $281M Cash Position - StockTitan
Caribou Biosciences initiates CB-010 GALLOP Phase 1 trial in lupus - TipRanks
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 - The Manila Times
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):